Contributing Author: Chris Mycek, President at WORLEY Pivoting to virtual….Google it, you’ll find it’s a common current theme that will have enduring repercussions on how things get done. Zoom is a new household word, and now a verb as well. Amazon Prime, Netflix, FedEx, are all booming. Nesting at home, with new entertainment centers, pools, and other home luxuries are also … [Read more...]
Speaking the Language of Powders
Author: Casey Muench Bickhardt, President, GEMCO In the pharmaceutical industry, the precise mixing and drying of powders can be critical to the safety, consistency, performance, and cost effectiveness of a wide range of tablets and capsules with trace levels of additives and active ingredients. A host of variables, such as powder size, shape, density, chemistry, static … [Read more...]
Healthcare Marketers Benefit by New Industry Collaboration Driving 360-degree Patient Targeting and Engagement
PRINCETON, N.J. and WILMINGTON, Del., Jan. 7, 2020 /PRNewswire/ -- healtheo360 and Data360, LLC announce a joint venture connecting healthcare marketers with patients and caregivers for valuable engagement with relevant content to improve disease state awareness. The patient journey, which winds through many decision points and influencers, requires that healthcare marketers … [Read more...]
Definitive Healthcare Acquires PatientFinder
Acquisition Accelerates Company’s Strategy of Developing Actionable Go-to-Market Solutions for the Healthcare Market FRAMINGHAM, MA – January 13, 2019 – Definitive Healthcare, the leading provider of data, insights, and analytics on the healthcare provider market, today announced the acquisition of PatientFinder, a software analytics firm that helps life science companies … [Read more...]
Veeva Introduces Payment Solution for Clin Research Sponsors/CROs and Sites
The success of clinical trials depends on an adequate supply of experienced clinical site investigators. However, the pool of qualified investigators has been shrinking in recent years and a growing proportion of “one-and-done” investigators stop leading clinical trials after one trial. Nearly one-third (30%) of all sites engaged in research currently are first timers. The loss … [Read more...]